clinical trial · NCT04331119

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Washington University School of Medicine →·phase2·active not recruiting·n = 17

T-Cell LymphomaDuvelisibPeripheral blood draw

brief summary

The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant in patients with T-cell lymphomas will be safe and well tolerated, and will improve progression free survival.

started

Jul 23, 2020

primary completion

Apr 22, 2026

completion

Apr 22, 2026

last updated

Dec 30, 2025

official title

Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol